eriodictyol has been researched along with Bone Loss, Osteoclastic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kang, JH; Lee, J; Noh, AL; Yim, M; Zheng, T | 1 |
| Huang, Y; Liu, Q; Quinn, JM; Song, F; Tan, R; Tickner, J; Xu, J; Yang, M; Zhang, G; Zhao, J; Zhou, L | 1 |
2 other study(ies) available for eriodictyol and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Eriodicyol inhibits osteoclast differentiation and ovariectomy-induced bone loss in vivo.
Topics: Animals; Bone Density; Bone Resorption; Cell Differentiation; Cells, Cultured; Dose-Response Relationship, Drug; Flavanones; Flavonoids; Mice; Mice, Inbred ICR; Osteoclasts; Ovariectomy; RANK Ligand; Structure-Activity Relationship | 2015 |
Eriodictyol Inhibits RANKL-Induced Osteoclast Formation and Function Via Inhibition of NFATc1 Activity.
Topics: Animals; Bone Marrow Cells; Bone Resorption; Cell Differentiation; Flavanones; Mice; NF-kappa B; NFATC Transcription Factors; Osteoclasts; Proto-Oncogene Proteins c-fos; RANK Ligand; Signal Transduction | 2016 |